PURPOSE: Overexpression of the receptor tyrosine kinase Axl is implicated in several cancers. Therefore, we conducted this study to determine the expression of Axl and its ligand Gas6 in various renal cell carcinoma (RCC) types and in oncocytoma. EXPERIMENTAL DESIGN: Real-time quantitative reverse transcription-PCR was used to quantify tumor mRNA levels for Axl and Gas6 in a cohort (n = 221) of RCC patients. Serum levels of soluble sAxl and Gas6 proteins were measured using specific ELISA assays (n = 282). The presence of Axl protein in tumor tissue was evaluated by immunohistochemistry (n = 294). Results were correlated to tumor-associated variables, clinical biochemical tests, and patient survival. RESULTS: Tumor Axl mRNA levels correlated independently to survival when assessed against tumor stage and grade. In the study group, the median cancer-specific survival of all RCC patients during 307 months of follow-up was 55 months (confidence interval, +/-40.4). The 25% of patients with lowest tumor Axl mRNA levels had significantly better survival than the rest (P = 0.0005), with 70% of the patients still alive at the end of follow-up. In contrast, in patients with medium-high Axl mRNA, only 25% were alive at the end of follow-up. Tumor Gas6 mRNA levels correlated to survival, tumor-associated variables, and disease severity as did serum levels of soluble sAxl and Gas6 protein. However, no correlation between Axl protein in tumor tissue and survival was found. CONCLUSIONS: Axl and Gas6 expression in RCC are associated with tumor advancement and patient survival. In particular, low tumor Axl mRNA levels independently correlated with improved survival.
PURPOSE: Overexpression of the receptor tyrosine kinase Axl is implicated in several cancers. Therefore, we conducted this study to determine the expression of Axl and its ligand Gas6 in various renal cell carcinoma (RCC) types and in oncocytoma. EXPERIMENTAL DESIGN: Real-time quantitative reverse transcription-PCR was used to quantify tumor mRNA levels for Axl and Gas6 in a cohort (n = 221) of RCCpatients. Serum levels of soluble sAxl and Gas6 proteins were measured using specific ELISA assays (n = 282). The presence of Axl protein in tumor tissue was evaluated by immunohistochemistry (n = 294). Results were correlated to tumor-associated variables, clinical biochemical tests, and patient survival. RESULTS:TumorAxl mRNA levels correlated independently to survival when assessed against tumor stage and grade. In the study group, the median cancer-specific survival of all RCCpatients during 307 months of follow-up was 55 months (confidence interval, +/-40.4). The 25% of patients with lowest tumorAxl mRNA levels had significantly better survival than the rest (P = 0.0005), with 70% of the patients still alive at the end of follow-up. In contrast, in patients with medium-high Axl mRNA, only 25% were alive at the end of follow-up. TumorGas6 mRNA levels correlated to survival, tumor-associated variables, and disease severity as did serum levels of soluble sAxl and Gas6 protein. However, no correlation between Axl protein in tumor tissue and survival was found. CONCLUSIONS:Axl and Gas6 expression in RCC are associated with tumor advancement and patient survival. In particular, low tumorAxl mRNA levels independently correlated with improved survival.
Authors: Xianzhou Song; Hua Wang; Craig D Logsdon; Asif Rashid; Jason B Fleming; James L Abbruzzese; Henry F Gomez; Douglas B Evans; Huamin Wang Journal: Cancer Date: 2010-10-04 Impact factor: 6.860
Authors: Cristina Bárcena; Milica Stefanovic; Anna Tutusaus; Leonel Joannas; Anghara Menéndez; Carmen García-Ruiz; Pau Sancho-Bru; Montserrat Marí; Joan Caballeria; Carla V Rothlin; José C Fernández-Checa; Pablo García de Frutos; Albert Morales Journal: J Hepatol Date: 2015-04-20 Impact factor: 25.083
Authors: Toni K Choueiri; Susan Halabi; Ben L Sanford; Olwen Hahn; M Dror Michaelson; Meghara K Walsh; Darren R Feldman; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Daniel J George; Michael J Morris Journal: J Clin Oncol Date: 2016-11-14 Impact factor: 44.544
Authors: Kenji Yumoto; Matthew R Eber; Janice E Berry; Russell S Taichman; Yusuke Shiozawa Journal: Clin Cancer Res Date: 2014-04-22 Impact factor: 12.531
Authors: Gunther Boysen; Damaris Bausch-Fluck; Claudio R Thoma; Anna M Nowicka; Daniel P Stiehl; Igor Cima; Van-Duc Luu; Adriana von Teichman; Thomas Hermanns; Tullio Sulser; Barbara Ingold-Heppner; Niklaus Fankhauser; Roland H Wenger; Wilhelm Krek; Peter Schraml; Bernd Wollscheid; Holger Moch Journal: Neoplasia Date: 2012-06 Impact factor: 5.715
Authors: Jennifer Schlegel; Maria J Sambade; Susan Sather; Stergios J Moschos; Aik-Choon Tan; Amanda Winges; Deborah DeRyckere; Craig C Carson; Dimitri G Trembath; John J Tentler; S Gail Eckhardt; Pei-Fen Kuan; Ronald L Hamilton; Lyn M Duncan; C Ryan Miller; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Jing Liu; Weihe Zhang; Chao Yang; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Janiel M Shields; Douglas K Graham Journal: J Clin Invest Date: 2013-04-15 Impact factor: 14.808
Authors: David Cella; Bernard Escudier; Nizar M Tannir; Thomas Powles; Frede Donskov; Katriina Peltola; Manuela Schmidinger; Daniel Y C Heng; Paul N Mainwaring; Hans J Hammers; Jae Lyun Lee; Bruce J Roth; Florence Marteau; Paul Williams; John Baer; Milan Mangeshkar; Christian Scheffold; Thomas E Hutson; Sumanta Pal; Robert J Motzer; Toni K Choueiri Journal: J Clin Oncol Date: 2018-01-29 Impact factor: 44.544